Vivani Medical, Inc. (Nasdaq: VANI) has released its financial results for the fourth quarter and full year ended December 31, 2025, alongside a business update. The company reported a net loss of $26.6 million for the year, compared to a loss of $23.5 million in 2024. This increase in net loss is attributed to higher clinical trial expenses and professional services costs. Despite the losses, Vivani highlighted significant progress in its clinical studies, particularly the successful completion of its first-in-human study, LIBERATE-1, which demonstrated the feasibility of its NanoPortal technology with semaglutide, the active ingredient in popular weight management drugs like Wegovy and Ozempic. The company is advancing its NPM-139 semaglutide implant towards a Phase 1 clinical study, with results expected by the end of 2026. Vivani's cash position remains solid, with $16.2 million in cash and equivalents as of December 31, 2025, which is projected to fund operations into mid-2027. The company is also preparing for commercial-scale manufacturing and has made significant strides in its operational capabilities. Overall, while the financial results reflect ongoing losses, the advancements in clinical trials and a strong cash position suggest a positive outlook for Vivani Medical's future.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.